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To clarify whether me formation of thrombi could be
induced by atrial fibrillation itself or by fartirs predispos-
ing to atrial fibrillation such as milral stenosis, plasma
D-dimer levels (crass-linked fibrin degradation produetsl
were measured In 73 patients with chronic atrial fibrillation
(Group 1) and 21 patients without atria) fibrillation (Group
2), In Group 1, 49 of the 73 patients had factors predispos-
ing to •trial fibrillation such as valvular heart disease, and
the raining 24 had lone atria) fibrillation . In Group 2, 16
patients had organic heart disease and the remaining 5 had
a chest pain syndrome .
The plasma D-dimer level was significantly higher in
Atria] fibrillation is associated with systemic embolic epi-
sodes that can lead to catastrophic events (1-6). In a
retrospective autopsy study, Hinton et al . (1) observed that
patients with atrial fibrillation had a fivefold greater inci-
dence of systemic embolization than did a control group
without atrial fibrillation
. The Framingham Study (2) found
that stroke was five times more common in the patients with
atria) fibrillation than in an age-matched group in sinus
rhythm . In general . the genesis of embolic episodes is
common to thrombosis. However, the tendency to increased
clotting is, to our knowledge, previously unreported in
patients with atria) fibrillation . Furthermore, it remains to be
clarified whether atria) fibrillation with specific predisposing
factors, such as milral stenosis, causes greater increased
clotting than does lone atrial fibrillation . If it is true that
patients with lone atrial fibrillation without its predisposing
factors are at increased risk of clotting, prophylactic antieo-
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agulant therapy should be recommended for the prevention
of intracardiovascularthrombi (7).
whether or not predispos-
ing factors to atrial fibrillation such as valvular heart disease
coexist .
In this study . we attempted to demonstrate that atria)
fibrillation itself rather than the predisposing factors to •trial
fibrillation contributed to intraeardiovascutar clotting, as
evidenced by increased levels of plasma D-dimer .
Methods
Study patients
. Eighty-five patients with chronic atrial
fibrillation who visited Osaka Prefectural Hospital between
February 1988 and July 1988 were studied. Chronic atrial
fibrillation was dafined as constant atrial fibrillation docu-
mented electrocardiographically during any hospital visit (at
least three hospital visits) . Twelve of these patients were
excluded from the study because they had severely limited
venous access, chronic renal failure, a known malignancy or
were receiving anticoagulant medication . The remaining 73
patients considered to be eligible for this study were desig-
nated as Group 1(39 men and 34 women, mean age ~! . SEM
64 ± I years).
Of rite 73 patients in Group 1, 49 had a predisposing
factor to arrinl fibrillation : valvular heart disease (n = 38,
including 16 with milral stenosis), ischemic heart disease
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(n = 5), hypertrophic cardiomyopathy (n = 2) . dilated
cardiomyopathy (n = 2) and myocarditis (n = 2) . The
remaining 24 patients showed no clinical evidence of organic
heart disease. In these patients . atria) fibrillation was defined
as lone atrial fibrillation .
Group 2 consisted of 21 patients in sinus rhythm (9 men
and 12 women, age 61 ± 2 years) who volunteered to
participate in this study. Of these 21 patients, 16 had organic
heart disease : valvular heart disease (n = 9, including 4 with
Initial stenosis), ischemic heart disease (n = 6) and hyper-
trophic cardiomyopathy (n = 1)
. The remaining five patients
had no organic heart disease (chest pain syndrome) . All the
patients gave informed consent to the study . Sixteen patients
in Group I had a past history of systemic embolic episodes .
Blood samples. Whole blood samples (approximately
3 ml) were drawn from the antecubital vein by careful
atraumatic venipuncture
. Samples were collected with unin-
terrupted flow and 1
.6 ml aliquot samples were placed into
precooled plastic tubes (4'C)
containing 0 .4 ml of heparin
sodium (500 Wall) and aprolinin (10,000 U/m1) as the inhib-
itors of plasmin and thrombin . The tubes were immediately
inverted gently several times and promptly centrifuged at
1 .500 g for 10 min at 4°C . Plasma was separated immediately
and frozen quickly at -20'C for 524 h and subsequently at
-40°C for s3 days before assay . Immediately before assay,
plasma was thawed rapidly by incubation at 37°C for 5 min .
No specimen was frozen and thawed more than once before
assay .
Assay procedures . D-dimer levels were measured by an
enzyme immunoassay using two monoclonal antibodies,
DD-386122 and DD-4D21182. These antibodies were pre-
pared in BALB/c mice immunized with highly purified
human D-dimer, using conventional hybridoma technology
with NS-I myeloma cells (8). The enzyme immunoassay kit
(Dimertest EtA) was obtained from MAhCo . Briefly . after
polyvinyl microtiter plates (Dynatech) were coated with the
capture antibody (DD-386122) monospecific for an antigen
expressed on D-dimer and related complexes known to
contain cross-linked gamma-gamma chains, the plates were
incubated with a plasma sample diluted with phosphate-
buffered saline solution (pH 7 .4) containing 0 .2% Tween 20
(polyoxyethylene sorbitan monolaurate) and 0 .551 sodium
chloride for I h at room temperature . Plates were then
washed with the same buffer and incubated with the horse-
radish peroxidase-labeled tag antibody (DD-4D21182) for I h
at room temperature
. After the plates were washed with the
same buffer, a color reaction was started using activated
substrate (H2
0,/0' toluidine dihydrochloride) and was
stopped with sodium fluoride. Absorbance was read at 405
nm using a microtiter plate reader.
This assay is specific not only for measurement of D-
dimer, but also for measurement of other cross-linked gam-
ma-gamma chain complexes
. Neither fibrinogen nor fibrin-
ogen and fibrin degradation products with no cross-linked
Table 1 . Plasma D-Dimer Levels in Patients With Chronic Anial
Fibrillation (Group I, n = 73) and Those in Sinus Rhythm (Group
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'p < 0.01 versus Group 2: tp < 0.01 versus patients with organic hear
disease in Group 2lorgan(c Me Ip < 0.01 versus patients without organic
hear disease in Group 21 Organic I - II . Values arc expressed as mean values
t SEW ranges are shown in parentheses.
gamma-gamma chain showed any reaction to this assay . The
conditions of this assay permitted the detection of D-dimer
levels ?20 ng/ml . The mean coefficient of variation was
5.8%.
Statistical analysis . All values of the clinical variables are
reported as mean values'_ standard error . Statistical com-
parison was performed using the Wilcoxon signed-rank test
for nonparametric distributions, with a limit of significance
of p = 0 .01 .
Results
There were no significant age or gender differences be-
tween patients in Group I and Group 2 .
Plasma D-dimer levels (Table 1)
.
The plasma D-dimer
level was significantly higher in Group I than in Group 2
patients (Fig. 1), in Group I patients with organic heart
disease than in Group 2 patients with organic heart disease
and in Group I patients without organic heart disease than in
Group 2 patients without organic heart disease
. There were
no significant differences in plasma D-dimer level between
patients with and without organic heart disease in both
Group I and Group 2
. Furthermore, the plasma D-dimer
level in Group I patients with mitral stenosis (range 30 to 382
nglml, mean 143 ± 25 ng/ml) was significantly higher than in
Group 2 patients with mitral stenosis (range 58 to 87 nglml,
mean 70 ± 6 ng/ml) . No significant differences in plasma
D-dimer level were observed between Group I patients with
mitral stenosis and Group I patients with lone atrial fibrilla-
tion and between Group 2 patients with mitral stenosis and
Group 2 patients with chest pain syndrome (Fig . 1).
History of systemic embolism. In Group I patients, a
systemic embolic episode had occurred in 16 patients (4 of
the 24 patients with lone atria) fibrillation and 12 of the 49
patients with organic heart disease). No Group 2 patients
had a past history of a systemic embolic episode. In Group I
patients with a past history of a systemic embolic episode,
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Figure 1.
Plasma D-dimer levels in patients with atrial fibrillation
(Af) (Group 1 .
n = Bland sinus rhythm (SRI (Group 2. n = 21) are
shown with mean values ± SEM
. A significant difference is seen
between the two groups (p < 0.01) . Open trimgles indicate the
plasma Ddimer level in patients with mitral stenosis
; open circles
the level in patients with other organic heart disease and closed
drdes the level in patients without organic heart disease.
the plasma D-dimer level was 196 ± 73 ngrml
; in those
without a past history of a systemic embolic episode, the
level was 140 ± 19 nglml
. The plasma D-dimer level in
patients with a past history of an embolic episode
. showed
no significant difference from the level in patients without an
embolic episode (Fig. 2.)
Discussion
Plasma D-dimer identifies the presence of cross-linked
fibrin degradation products without interference from fibrin-
ogen and noncross-linked fibrin
(9,10) . Therefore, the
plasma D-dimer level reflects the intravascular clotting level
(11-14)
. For this reason, plasma D-dimer levels were mea-
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Figure, 2 . Plasma D-dimer levels in patients in Group I with (+) and
without
I-)
a past history of an embolic episode (values are mean
values ± SEM)
. There is no significant difference between patients
with and without a past history of an embolic episode.
sured to clarify whether increased intracardiovascular clot-
ting could be induced in patients with atriel fibrillation .
The borstal plea Mom lavd . Whitaker et al. (9)
reported that the mean plasma D-dimer level in a normal
control group was 75 ngfml and the maximal level 144 ng/ml;
the normal range of plasma D-dimer was thus established as
< 144 ng/ml (9)
.
In our study, the plasma D-dimer level was
150 ± 19 ng/ml in Group I (chronic atrial fibrillation) and
61 ± 3 ng/ml in Group 2 (sinus rhythm) . These values were
not particularly high
. Therefore, the assay used for plasma
D-dimer in this study must be examined for its accuracy of
measurement for low values of plasma D-dimer. The plasma
D-dimer level was measured by an enzyme immunoassay .
Our assay conditions permitted the detection of plasma
D-dimer levels ±20
rig/ml . The mean coefficient of variation
of this assay was 6.3% for the low concentration (34 t
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2 nglmq and 5 .6% for the high concentration (306 m 16 References
ngfmll. Consequently . this assay could be considered to be
accurate for low concentrations of plasma D-dimer. There-
fore, the discrepancies between the values of plasma D-
dimer in the report of Whitaker et al . (9) and those in our
report might be caused by the difference related to subjects
and race.
Patients with chronic atdal fibrillation (Group t) versus
sinus rhythm (Group 2) . In this study, the plasma D-dimer
level was significantly higher in Group I than in Group 2
patients . Furthermore, the plasma D-dimer level in patients
with organic heart disease was significantly higher in patients
in Group I than Group 2. These findings may be explained by
the difference in the severity of organic heart disease be-
tween Group I and Group 2 because the severity of organic
heart disease such as mitral stenosis is reflected by the
presence of atrial fibrillation . However, even if the severity
of organic heart disease was different between patients in
Group I and Group 2. we could not find a significant
difference in D-dimer level between patients with organic
heart disease and those with tone ahiat fibrillation in Group
I and between patients with and without organic heart
disease in Group 2 . These findings indicate that the most
important factor that induces increased intracardiovascular
clotting in patients with atrial fibrillation would be Burial
fibrillation itself, not the presence of specific predisposing
factors such as mitral stenosis
.
History of systemic embolism .
A history of systemic em-
bolization has been generally considered to have a close
relation with recurrent embolism . Therefore, anticoagulant
therapy has been recommended for patients with a past
history of systemic embolism to prevent recurrent intracar-
diovascular clotting (15,16). In our study, however, the
plasma D-dimer level in Group I patients with a past history
of an embolic event was not significantly different from that
in patients without a past history of an embolic event . This
finding strongly suggests that an increased clotting tendency
is present in patients with atria) fibrillation whether or not
there is a past history of systemic embolism
.
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